Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Rein Therapeutics (RNTX)
NASDAQ:RNTX
Holding RNTX?
Track your performance easily
RNTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.61 - $7.42
Previous CloseN/A
VolumeN/A
Average Volume (3M)118.11K
Market Cap
$47.67M
Enterprise Value$104.02M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.64
Next EarningsN/A
EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.11
Shares Outstanding21,665,941
10 Day Avg. Volume76,980
30 Day Avg. Volume118,107
Standard Deviation0.38
R-Squared0.10
Alpha-0.00279
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$8.00Price Target Upside221.29% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RNTX FAQ
What was Rein Therapeutics’s price range in the past 12 months?
Rein Therapeutics lowest stock price was $1.61 and its highest was $7.42 in the past 12 months.
What is Rein Therapeutics’s market cap?
Rein Therapeutics’s market cap is $47.67M.
When is Rein Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Rein Therapeutics’s earnings last quarter?
Rein Therapeutics released its earnings results on Nov 14, 2024. The company reported -$0.27 earnings per share for the quarter, missing the consensus estimate of -$0.245 by -$0.025.
Is Rein Therapeutics overvalued?
According to Wall Street analysts Rein Therapeutics’s price is currently Undervalued.
Does Rein Therapeutics pay dividends?
Rein Therapeutics does not currently pay dividends.
What is Rein Therapeutics’s EPS estimate?
Rein Therapeutics’s EPS estimate is -0.18.
How many shares outstanding does Rein Therapeutics have?
Rein Therapeutics has 21,665,941 shares outstanding.
What happened to Rein Therapeutics’s price movement after its last earnings report?
Rein Therapeutics reported an EPS of -$0.27 in its last earnings report, missing expectations of -$0.245. Following the earnings report the stock price went down -13.293%.
Which hedge fund is a major shareholder of Rein Therapeutics?
Currently, no hedge funds are holding shares in RNTX
---
Rein Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (221.29% Upside)
$8.00 (221.29% Upside)
Insider Transactions
Bought Shares
Worth $897.6 over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 2.8%
Last 30 Days ▼ 4.8%
Last 30 Days ▼ 4.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.27%
12-Months-Change
Fundamentals
Return on Equity
-54.95%
Trailing 12-Months
Asset Growth
712.80%
Trailing 12-Months
Company Description
Rein Therapeutics
Aileron Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead products candidate, ALRN-6924 which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky in June 2005 and is headquartered in Cambridge, MA.
---
RNTX Stock 12 Month Forecast
Average Price Target
$8.00
▲(221.29% Upside)
Technical Analysis
Karyopharm Therapeutics
―
TG Therapeutics
―
Actinium Pharmaceuticals
―
Cellectar Biosciences
―
Best Analysts Covering RNTX
1 Year
1 Year Success Rate
1/3 ratings generated profit
1 Year Average Return
-38.00%
reiterated a buy rating 10 months ago
Copying Aydin Huseynov's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -38.00% per trade.
---